About this item:

632 Views | 488 Downloads

Author Notes:

Correspondence to: Leon Bernal-Mizrachi, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, 1365 Clifton Road, C1152B, GA 30322, USA, Telephone: 404-778-1670, Email: lbernal@emory.edu

The authors thank Dr. Sagar Lonial and Dr. Jean L. Koff for their critical review and helpful comments.


Research Funding:

This work was supported by the National Institutes of Health [CA15121 to H.I.S., CA109335 and CA122105 to I.S.L. and CA127910 and CA129968 to L.H.B]; the National Cancer Institute [K01CA104079 to H.I.S.]; Georgia Cancer Coalition Distinguished Scholar Award to H.I.S, L.H.B; Lymphoma Research Foundation and the Dwoskin Family, Recio Family and Anthony Rizzo Family Foundations to I.S.L. and Byron Davis Research Fund and Crissey Hematology and Medical Oncology Research Fund to L. B-M.


  • Science & Technology
  • Life Sciences & Biomedicine
  • Oncology
  • diffuse large cell lymphoma
  • NF-B
  • chromosome stability
  • P53

Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF-kappa B pathway

Show all authors Show less authors


Journal Title:

International Journal of Cancer


Volume 136, Number 10


, Pages 2341-2351

Type of Work:

Article | Post-print: After Peer Review


Diffuse large B cell lymphoma (DLBCL) is the most common form of lymphoma in the United States. DLBCL comprises biologically distinct subtypes including germinal center-like (GCB) and activated-B-cell-like DLBCL (ABC). The most aggressive type, ABC-DLBCL, displays dysregulation of both canonical and noncanonical NF-κB pathway as well as genomic instability. Although, much is known about the tumorigenic roles of the canonical NF-kB pathway, the precise role of the noncanonical NF-kB pathway remains unknown. Here we show that activation of the noncanonical NF-κB pathway regulates chromosome stability, DNA damage response and centrosome duplication in DLBCL. Analysis of 92 DLBCL samples revealed that activation of the noncanonical NF-κB pathway is associated with low levels of DNA damage and centrosome amplification. Inhibiting the noncanonical pathway in lymphoma cells uncovered baseline DNA damage and prevented doxorubicin-induced DNA damage repair. In addition, it triggered centrosome amplification and chromosome instability, indicated by anaphase bridges, multipolar spindles and chromosome missegregation. We determined that the noncanonical NF-κB pathway execute these functions through the regulation of GADD45α and REDD1 in a p53-independent manner, while it collaborates with p53 to regulate cyclin G2 expression. Furthermore, this pathway regulates GADD45α, REDD1 and cyclin G2 through direct binding of NF-κB sites to their promoter region. Overall, these results indicate that the noncanonical NF-κB pathway plays a central role in maintaining genome integrity in DLBCL. Our data suggests that inhibition of the noncanonical NF-kB pathway should be considered as an important component in DLBCL therapeutic approach.

Copyright information:

© 2014 UICC.

Export to EndNote